Skip to content

Released Aug 16, 2021, before the open

10-Q filed Aug 16, 2021, 47 days after period end · 0001558370-21-011752

Q2 2021 · 10-Q
Revenue$6.43M−41.4% vs Q2 2020−43.2% vs Q1 2021
Net Income-$11.24MN/M vs Q2 2020N/M vs Q1 2021
EPS Diluted-$0.25N/M vs Q2 2020N/M vs Q1 2021
Operating Income-$9,166,000N/M
Operating Cash Flowderived$6,516,000N/M
Free Cash Flowderived$6,235,000N/M
Margins · derived
Operating margin-142.6%−122.2 pt vs Q2 2020
Net margin-174.9%−137.1 pt vs Q2 2020

What the release said

The release

Same quarter

MetricQ2 2021Q2 2020Q2 2019Q2 2018
Revenue$6.43M$10.97M$12.25M$2.01M
Net Income-$11.24M-$4.15M-$7.74M-$8.46M
EPS Diluted-$0.25-$0.13-$0.52-$0.06

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR